[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:tacstd2-wt-allele":3},{"name":4,"total":5,"recruiting":5,"trials":6},"TACSTD2 wt Allele",8,[7,15,21,27,34,40,46,52],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06524544","A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer",[11],"Phase 3","RECRUITING","2026-08-26T02:16:48.735701Z","2026-07-24T01:27:14.888700Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06312137","A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)",[11],"2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.749560Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06841354","A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011\u002FTroFuse-011)",[11],"2026-08-26T02:18:59.761994Z","2026-06-16T05:54:07.924230Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT05838521","A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer",[31],"Phase 2","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.667759Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":13,"content_modified":39},"NCT07101432","Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)",[38],"Phase 1","2026-05-05T02:43:27.433693Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":44,"content_modified":45},"NCT07291037","Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations",[11],"2026-08-26T02:15:44.309045Z","2026-05-05T02:35:31.692117Z",{"nct_id":47,"title":48,"phases":49,"status":12,"updated_at":50,"content_modified":51},"NCT06066424","Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)",[38],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:28.221368Z",{"nct_id":53,"title":54,"phases":55,"status":12,"updated_at":56,"content_modified":57},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[31],"2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z"]